View Item 

Show simple item record

The captopril-digoxin multicenter resarch group study on the comparative steps of captopril and digoxin in patients with mildmoderate heart failure: Implications for therapy
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorGoldstein, Sidneyen_US
dc.date.accessioned2006-09-11T15:02:07Z
dc.date.available2006-09-11T15:02:07Z
dc.date.issued1989-01en_US
dc.identifier.citationPitt, Bertram; Goldstein, Sidney; (1989). "The captopril-digoxin multicenter resarch group study on the comparative steps of captopril and digoxin in patients with mildmoderate heart failure: Implications for therapy." Cardiovascular Drugs and Therapy 3(1): 7-9. <http://hdl.handle.net/2027.42/44603>en_US
dc.identifier.issn0920-3206en_US
dc.identifier.issn1573-7241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/44603
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2487524&dopt=citationen_US
dc.description.abstractIt is argued that the basis of therapy in a patient with mild-to-moderate congestive heart failure should be a combination of a diuretic and a converting enzyme inhibitor, with the further addition of digoxin if necessary.en_US
dc.format.extent276666 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers; Springer Science+Business Mediaen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherCardiologyen_US
dc.subject.otherCaptoprilen_US
dc.subject.otherDigoxinen_US
dc.subject.otherCongestive Heart Failureen_US
dc.titleThe captopril-digoxin multicenter resarch group study on the comparative steps of captopril and digoxin in patients with mildmoderate heart failure: Implications for therapyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Cardiology, University of Michigan Medical Center, 48109-0366, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumDivision of Cardiology, University of Michigan Medical Center, 48109-0366, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid2487524en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/44603/1/10557_2005_Article_BF01881521.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF01881521en_US
dc.identifier.sourceCardiovascular Drugs and Therapyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10557_2005_Article_BF01881521.pdf
Size:
270.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.